TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A systematic review and meta-analysis covering nearly 15.9 million people found ADHD was associated with a 71% higher risk of death from any cause, as well as higher risks of suicide, injury and natural-cause mortality. ADHD medication use was associated with lower all-cause mortality in just three studies, a finding the researchers said should be interpreted cautiously.
A systematic review and meta-analysis of 19 studies involving 15,920,970 people found that ADHD was associated with a 71% higher risk of death from any cause than not having ADHD, consistent with research on other health risks linked to ADHD. The researchers also reported elevated risks of suicide, injury and natural-cause mortality, while a separate analysis associated ADHD medication use with lower mortality; that finding drew on only three studies.
In the review, Joshua Stott, PhD, of University College London, and colleagues reported an all-cause mortality hazard ratio of 1.71 for people with ADHD compared with others (95% confidence interval 1.31 to 2.24). The analysis also found higher risks of suicide (HR 1.89), intentional or unintentional injury (HR 1.55) and natural-cause mortality (HR 1.27). The results were published in JAMA Network Open.
The researchers conducted five meta-analyses using results from subsets of the included studies: nine studies for all-cause mortality, five for suicide, four for injury, three for natural-cause mortality and three for all-cause mortality among people using ADHD medication. Medication use was associated with a 25% lower all-cause mortality risk (HR 0.75, 95% CI 0.64 to 0.87), but the authors cautioned that the small number of studies and possible differences between treated and untreated groups limit what can be concluded.
Studies qualified if they reported all-cause or cause-specific mortality among people with ADHD. Definitions varied and could include formal diagnostic criteria, self-identification, measures of ADHD traits or genetic risk scores. The review included people of all ages; 63.9% of participants were male. The source report says the first four mortality analyses showed substantial variation across studies, while the natural-cause analysis did not.
What the Mortality Findings Mean
The findings add to evidence that people with ADHD may face higher risks of several causes of death, extending the concern beyond injuries or suicide alone. The results may matter to patients, families and clinicians because they point to potential areas for support, including mental health, injury prevention and access to health care. The review itself, however, identifies associations; it does not establish that ADHD directly causes the increased mortality.
Stott told MedPage Today that the results do not mean everyone with ADHD will die young or that increased mortality is inevitable. He said they underline the importance of accurate diagnosis and access to treatment. The medication association is not proof that medication prevents deaths: researchers warn that treated and untreated people may differ in health status, access to care, illness severity, socioeconomic circumstances, adherence and other conditions.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Review
The team included quantitative studies available through July 2025, bringing together earlier research on mortality among people with ADHD. Some previous studies had reported a life-expectancy gap of six to seven years, but that estimate is not the main result of this meta-analysis and should not be treated as a prediction for an individual.
MedPage Today cited U.S. Centers for Disease Control and Prevention estimates that 15 million adults in the United States have ADHD and that nearly one in three take stimulant medication. The CDC also estimates that 7 million children ages 3 to 17 have an ADHD diagnosis. These U.S. figures describe ADHD prevalence and medication use; they are separate from the international studies pooled in the mortality review.
Jeffrey Newcorn, MD, of the Icahn School of Medicine at Mount Sinai, who was not involved in the review, told MedPage Today that adult ADHD is often diagnosed late and that many diagnosed adults do not receive treatment. His comments provide context about diagnosis and care, rather than a finding tested by this meta-analysis.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, PhD, of University College London, speaking to MedPage Today
ADHD safety and injury prevention products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Medication Analysis
The review cannot show that ADHD itself caused the higher mortality risks, or establish which factors explain the associations. The authors said possible pathways include impulsivity, emotional dysregulation and risk-taking contributing to injury; co-occurring depression contributing to suicide risk; and smoking, alcohol use, health-care barriers, cardiovascular disease or metabolic disorders affecting natural-cause mortality. These are potential explanations, not causes demonstrated by this analysis.
The medication finding is especially uncertain because it rests on three studies. The authors warned of residual confounding and confounding by indication: people who receive treatment may differ from those who do not in ways that also affect mortality. Differences in diagnostic definitions, access to care and participant characteristics across countries also complicate comparisons. The review reported substantial heterogeneity in several analyses, and many included studies had gender imbalances.
The reported hazard ratios compare groups in the studies; they do not give an individual’s absolute chance of dying or specify how many deaths would occur in a given population. The source report does not provide a single absolute risk estimate applicable to all people with ADHD.
As an affiliate, we earn on qualifying purchases.
Questions for Future Research
Further studies are needed to test whether the medication association holds in larger and more comparable groups, and to account for differences in health, treatment access and other conditions. Research that separates age groups, causes of death and treatment histories could help explain which risks are most relevant and where prevention or care improvements may help.
The review assessed research available through July 2025, so it does not include later studies. The source report describes no new trial or policy change tied to publication. For now, the authors’ conclusions concern population-level associations; people should discuss ADHD diagnosis and treatment decisions with a qualified health professional.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the review find about ADHD and mortality?
Across the included studies, ADHD was associated with a 71% higher all-cause mortality risk. The review also reported higher risks of suicide, injury and natural-cause mortality. These are group-level associations, not predictions for an individual.
Does the study show that ADHD causes early death?
No. The review combined observational research and found associations; it cannot establish that ADHD directly caused the reported differences. The researchers discussed several possible contributing pathways, but those explanations were not proven by the meta-analysis.
Did ADHD medication lower mortality?
Medication use was associated with a lower all-cause mortality risk in the analysis, but that result was based on only three studies. The researchers said differences between treated and untreated people could influence the association, so it does not prove medication prevents deaths.
How many people and studies were included?
The review included 19 studies and 15,920,970 participants. Not all participants or studies contributed to every analysis; for example, the medication analysis used three studies.
What remains unknown?
It remains unclear which factors account for the higher risks, whether the medication association holds in larger studies, and how findings vary by age, gender, diagnosis and access to care. The review does not provide an absolute mortality estimate for an individual with ADHD.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
